The AREDS2 report has recently been published with important implications for those afflicted with early stage AMD...
The AREDS2 report has recently been published with important implications for those afflicted with early stage AMD.
In summary, AREDS2 recruited 4203 volunteers with the non-advanced form of AMD, and all subjects received broad-spectrum antioxidants (vitamin C, vitamin E, beta-carotene, zinc and copper [AREDS1 formulation or variations thereof]) with additional treatment of lutein (L) and zeaxanthin (Z) (Treatment 1), or omega-3 fatty acids (Treatment 2), or L and Z and omega-3 fatty acids (Treatment 3), or placebo.
In brief, the AREDS 2 investigators reported:
This summary was created by Professor John Nolan, PhD, Principal Investigator, Fulbright Scholar, Howard Fellow, ERC Fellow, Macular Pigment Research Group, Vision Research Centre, Waterford Institute of Technology, Ireland.
A more detailed summary will be published in an upcoming print issue of Ophthalmology Times Europe.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.